Participated · Series B · Jan 2025

Labviva operates an AI procurement platform that connects researchers with suppliers of reagents, chemicals, consumables, and instrumentation, mapping products into scientific applications, techniques and protocols. The platform aggregates 90% of all life science suppliers, offering instant access to a diverse pool of sellers from major suppliers to small, local, and green-certified businesses. Suppliers can manage product content and products are mapped into scientific applications, enabling customers to compare products and prices based on company-specific pricing and rich product content. The service saves hours of manual research, reduces R&D costs, and helps avoid gaps in inventory replenishment while supporting contract compliance and sustainability objectives. Labviva's solution can operate as a stand-alone product or integrate with procurement systems including SAP Ariba, JAGGAER, Oracle Procurement Cloud, Microsoft Dynamics 365, and Coupa. Led by CEO Siamak Baharloo, the company raised $25M in a Series B to accelerate product development, bolster marketing and customer support, and expand internationally; 53 Stations’ Co-Founder Jason Pritzker will join the board as part of the round. Labviva offers an AI-driven SaaS marketplace that unifies product discovery and procurement for life sciences and research organizations. The platform aggregates thousands of suppliers and over 15 million products, mapping products to scientific applications, techniques, and protocols. Labviva integrates with leading procurement systems including SAP Ariba, JAGGAER, Oracle Procurement Cloud, Microsoft Dynamics 365, and Coupa to shorten implementation times and reduce research delays. Customers include global pharmaceutical and academic organizations; the company says it helps manage hundreds of millions of dollars in laboratory and research spend annually. Labviva plans to use the new funding to accelerate deployment at global customers, expand its global footprint, and launch new complementary product lines. Jennifer Lum of Biospring Partners will join Labviva’s board as part of the Series A round. Labviva offers an enterprise gateway marketplace (EGM) SaaS platform that integrates with major procurement systems like SAP Ariba, JAGGAER, Oracle Procurement Cloud, Microsoft Dynamics 365, and Coupa to connect institutions with a broad supplier network. The platform provides scientific context via a proprietary AI engine that maps products to applications and protocols, dynamically searching public databases for citations and protocols. Features include intuitive search, comparison shopping, reduced supplier onboarding, and advanced analytics that preserve procurement compliance and governance. Labviva targets purchasers in pharma, biotech, and research institutions and enables suppliers to manage product content mapped to scientific techniques. The company’s revenue model is subscription-based. The recent $8M Series Seed raise is intended to support further platform development, new product lines, and investments in operations and customer success.

Participated · Series C · May 2021

PathAI develops artificial intelligence-powered technology and an integrated platform for pathology aimed at improving diagnosis and treatment of diseases such as cancer. The company works with life sciences companies, researchers, pharmaceutical and diagnostic partners to advance precision medicine. PathAI plans to expand its product suite and commercial footprint to support the full lifecycle of drug development from translational research to global commercialization. It intends to develop AI-based pathology offerings for biopharma in disease indications beyond oncology and NASH. The company is also building a scalable workflow platform for CROs and reference lab partners to support broader deployments. PathAI emphasizes collaborations with pharmaceutical and diagnostic partners as part of its growth and product strategy. PathAI develops AI-powered technology and a platform intended to improve diagnostic accuracy and treatment efficacy for diseases such as cancer, using machine and deep learning. The company’s platform is applied to digital pathology and aims to advance pathology research and immuno-oncology development. With the new funding, PathAI plans to bolster and accelerate its clinical development capabilities and deepen partnerships with pharmaceutical companies. PathAI has worked strategically with industry partners to integrate insights from data into cancer therapy development. The company is headquartered in Boston and was founded in 2016. Including the latest financing, PathAI has raised a total of $90 million since its founding. PathAI is a Boston, MA-based provider of AI-powered technology for pathology research. Its platform uses machine and deep learning to improve diagnostic accuracy and treatment efficacy for diseases such as cancer. The company provides AI-powered research tools and services and works with leading life sciences companies and researchers to advance precision medicine. PathAI intends to use the funds from the LabCorp investment to expand clinical development of its AI-enabled computational pathology and to advance integration with clinical laboratories. The company is led by co-founder and CEO Andy Beck, M.D., Ph.D. Financially, LabCorp's strategic investment amount was not disclosed and follows a $60M round announced the prior month led by General Atlantic and General Catalyst. PathAI develops AI-powered technology and a flagship pathology research platform intended to improve the accuracy, reproducibility, and sub-typing of disease diagnoses such as cancer. The company works with leading life sciences firms and diagnostic laboratories to accelerate drug development and deliver faster, more predictive diagnostics to patients. PathAI plans to use new capital to enhance offerings to existing partners, drive continuous improvement of its platform, meet market demand, and fund R&D into new tools and medical devices. The company has secured quality management and information security certifications and publicly noted partnerships with Bristol-Myers Squibb and Novartis. Staff headcount grew from 25 to more than 60 over the past year, reflecting investments in machine learning, product development, regulatory affairs, and scientific program management. Headquartered in Boston, PathAI emphasizes scaling its solutions globally to improve patient diagnosis and treatment.

Led · Equity · Jul 2020

Abzena is a San Diego CDMO focused on drug substance and fill-finish manufacturing. The company is led by CEO Jonathan Goldman. It secured a $65 million investment to expand its manufacturing capacity. Abzena committed a portion of that investment to build out operations in the hot North Carolina scene. The capital is earmarked to grow drug substance and fill-finish capabilities. The article does not disclose operating metrics, past rounds, or additional financial details. Abzena is a Cambridge, UK-based global partnership research organization providing integrated discovery, development and manufacturing of biologics and antibody-drug conjugates (ADCs). Led by Jonathan Goldman, MD, the company offers integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing services. Abzena maintains resources around the world, with facilities in the US and UK. The company raised $10M in growth funding from Biospring Partners. Abzena intends to use the new capital to accelerate its growth plans.